Cyclic dipeptides exhibit synergistic, broad spectrum antimicrobial effects and have anti-mutagenic properties

International Journal of Antimicrobial Agents

Volumn 24, Issue 5, 2004, Pages 423-427

  Rhee, Ki Hyeong ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti mutagenic effects; Cyclo(L leucyl L prolyl); Cyclo(L phenylalanyl L prolyl); Synergism; Vancomycin resistant enterococci

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMUTAGENIC AGENT; CYCLO(LEUCYLPROLINE); CYCLO(PHENYLALANYLPROLINE); DIPEPTIDE; FURYLFURAMIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM MUTANT; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GROWTH INHIBITION; MICROCOCCUS LUTEUS; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; YEAST;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMUTAGENIC AGENTS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; VANCOMYCIN RESISTANCE;

EID: 7044247875     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.05.005     Document Type: Article

References (21)

1. Prasad C. Bioactive cyclic dipeptides. Peptides. 16:1995;151-164
2. Graz M., Hunt A., Jamie H., Grant G., Milne P. Antimicrobial activity of selected cyclic dipeptides. Pharmazie. 54:1999;772-775
3. Katrin S., Jorgen S., Anders B., John S. Lactobacillus plantarium MiLAB 393 produce the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(L-Phe-trans-4-OH-L-Pro) and 3-phenyllactic acid. Appl Environ Microbiol. 68:2002;4322-4327
4. 2+ catalysed cyclization procedure. J Org Chem. 41:1976;3433-3438
5. Rhee K.H. Isolation and characterization of Streptomyces sp. KH-614 producing anti-VRE (vancomycin-resistant enterococci) antibiotics. J Gen Appl Microbiol. 48:2002;321-327
6. Rhee K.H., Choi K.H., Kim C.J., Kim C.H. Identification of Streptomyces sp. AMLK-335 producing antibiotic substance inhibitory to VRE (vancomycin-resistant enterococci). J Micribiol Biotechnol. 11:2001;469-474
7. Erden I., Jale K.T., Birsen K., Pasa G. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents. 20:2002;384-386
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. fifth ed., standard M7-A6. Wayne, PA,USA: National Committee for Clinical Laboratory Standard; 2003.
9. Fahring R., Steinkamp-Zucht A. Co-recombiogenic and anti-mutagenic effects of diethylhexylphthalate, inactiveness of pentachlorophenol in the spot test with mice. Mutat Res. 354:1996;59-67
10. Matsushima M, Sugimura T, Nagao T, Shirai A, Sawamur M, Factors modulating mutagenecity in microbial test. In: North KH, Garner RC, editors. Short-term test system for directing mutagens and carcinogens. Berlin: Springer. p. 273-85.
11. Grey D., Hamilton-Miller J.M., Brumfitt W. Combined action of sulphamethoxazole and trimethoprim against clinically-isolated sulphonamide-resistant bacteria. Chemotherapy. 25:1979;296-302
12. King T.C., Schlessinger D., Krogstad D.J. The assessment of antimicrobial combinations. Rev Infect Dis. 3:1981;627-633
13. Niku-Paavola M.L., Laitila A., Mattila-Sandholm T., Haikara A. New type of antimicrobial compounds produced by Lactobacillus plantarum. J Appl Microbiol. 87:1999;29-35
14. Lambert R.J., Johnston M.D., Hanlon G.W., Denyer S.P. Theory of antimicrobial combinations: biocide mixtures-synergy or addition? J Appl Microbiol. 94:2003;747-759
15. Saito H., Tomioka H., Sato K., Dekio S. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobial against Mycobacterium leprae infection induced in nude mice. Int J Lepr Other Mycobact Dis. 62:1994;43-47
16. Shlaes D.M., Ette L., Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combination of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother. 35:1991;776-779
17. Dutka-Malen S., Evers S., Murin C.M., Soly D., Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically revertant enterococci by PCR. J Clin Microbiol. 33:1995;24-27
18. Free L, Sahm DF. Detection of enterococcal vancomycin resistance by multiplex PCR. In: Persing DH, editor. PCR Protocols for emerging infections diseases, a supplement to diagnostic molecular microbiology: principles and applications. Washington, DC: ASM Press. p. 150-5.
19. Rhee K.-H. Inhibition of DNA topoisomerase I by cyclo(L-prolyl-L- phenylalanyl) isolated from Streptomyces sp. AMLK-335. J Microbiol Biotechol. 12:2002;1013-1016
20. Milne PJ, Hunt AL, Rostoll K, Vanderwalt JJ, Graz CJM. The biological activity of selected cyclic dipeptides. 1998;50:1331-7.
21. DeFlora S. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Mutat Res. 402:1998;151-158